他米巴罗汀(Tamibarotene) - 药物靶点：RARα_在研适应症：急性早幼粒细胞白血病，RARα阳性骨髓增生异常综合征，常染色体显性多囊肾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Retinobenzoic acid、Tamibaro、Tamibarotene (JAN/INN)

+ [18]

靶点

RARα

作用机制

RARα激动剂(维甲酸受体α激动剂)

治疗领域

肿瘤血液及淋巴系统疾病其他疾病+ [2]

在研适应症

急性早幼粒细胞白血病RARα阳性骨髓增生异常综合征常染色体显性多囊肾病+ [1]

非在研适应症

晚期肝细胞癌晚期非小细胞肺癌乳腺癌+ [7]

原研机构

Nippon Shinyaku Co., Ltd.

在研机构

Syros Pharmaceuticals, Inc.

Rege Nephro Co. Ltd.初创企业Toko Pharmaceutical Industrial Co. Ltd.

非在研机构

LadRx Corp.R&R, Inc.

Zeria Pharmaceutical Co., Ltd.

最高研发阶段批准上市

首次获批日期

日本 (2005-04-11),

急性早幼粒细胞白血病

最高研发阶段(中国)-

特殊审评快速通道 (美国)、孤儿药 (欧盟)、孤儿药 (美国)

登录后查看时间轴

结构

分子式C22H25NO3

InChIKeyMUTNCGKQJGXKEM-UHFFFAOYSA-N

CAS号94497-51-5

关联

29

项与他米巴罗汀相关的临床试验

NCT06289998 / Recruiting临床2期

Phase IIa Clinical Trial of Tamibarotene in Patients With Autosomal Dominant Polycystic Kidney Disease

Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease

开始日期2023-12-22

申办/合作机构

Rege Nephro Co. Ltd.初创企业

JPRN-jRCT2011230055 / Suspended临床2期IIT

Phase IIa clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease

开始日期2023-12-12

申办/合作机构-

NCT06085638 / Withdrawn临床1/2期IIT

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

To learn if adding venetoclax to the chemotherapy combination of tamibarotene and azacitidine is more effective than tamibarotene and azacitidine alone in treating higher-risk CMM

开始日期2023-09-14

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与他米巴罗汀相关的临床结果

登录后查看更多信息

100 项与他米巴罗汀相关的转化医学

登录后查看更多信息

100 项与他米巴罗汀相关的专利（医药）

登录后查看更多信息

259

项与他米巴罗汀相关的文献（医药）

2024-07-22·BRITISH JOURNAL OF CANCER

Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade

Article

作者: Sassa, Naoto ; Tsukamoto, Tetsuya ; Ando, Ryota ; Hinohara, Kunihiko ; Kawashima, Hiroki ; Takahashi, Masahide ; Murakami, Takashi ; Sano, Tomoyasu ; Enomoto, Atsushi ; Akamatsu, Shusuke ; Mizutani, Yasuyuki ; Owaki, Takayuki ; Miyai, Yuki ; Akashi, Tomohiro ; Ishii, Makoto ; Hase, Tetsunari ; Yamamoto, Masami ; Shiraki, Yukihiro ; Matsukawa, Yoshihisa ; Mii, Shinji ; Esaki, Nobutoshi ; Nomura, Sachiyo ; Maeda, Motohiro ; Ishikawa, Takuya ; Yuguchi, Yuri ; Kato, Katsuhiro ; Iida, Tadashi

Abstract:

Background:

The proliferation of cancer-associated fibroblasts (CAFs) hampers drug delivery and anti-tumor immunity, inducing tumor resistance to immune checkpoint blockade (ICB) therapy. However, it has remained a challenge to develop therapeutics that specifically target or modulate CAFs.

Methods:

We investigated the involvement of Meflin+ cancer-restraining CAFs (rCAFs) in ICB efficacy in patients with clear cell renal cell carcinoma (ccRCC) and urothelial carcinoma (UC). We examined the effects of Am80 (a synthetic retinoid) administration on CAF phenotype, the tumor immune microenvironment, and ICB efficacy in cancer mouse models.

Results:

High infiltration of Meflin+ CAFs correlated with ICB efficacy in patients with ccRCC and UC. Meflin+ CAF induction by Am80 administration improved ICB efficacy in the mouse models of cancer. Am80 exerted this effect when administered prior to, but not concomitant with, ICB therapy in wild-type but not Meflin-deficient mice. Am80-mediated induction of Meflin+ CAFs was associated with increases in antibody delivery and M1-like tumor-associated macrophage (TAM) infiltration. Finally, we showed the role of Chemerin produced from CAFs after Am80 administration in the induction of M1-like TAMs.

Conclusion:

Our data suggested that Am80 administration prior to ICB therapy increases the number of Meflin+ rCAFs and ICB efficacy by inducing changes in TAM phenotype.

2024-06-28·MEDICINE

Identification of shared disease marker genes and underlying mechanisms between rheumatoid arthritis and Crohn disease through bioinformatics analysis

Article

作者: Shen, Ying ; Peng, Peifei

As chronic autoimmune inflammatory diseases, rheumatoid arthritis (RA) and Crohn disease (CD) are closely associated and display a significant positive correlation. However, the underlying mechanisms and disease markers responsible for their cooccurrence remain unknown and have not been systematically studied. Therefore, this study aimed to identify key molecules and pathways commonly involved in both RA and CD through bioinformatic analysis of public sequencing databases. Datasets for RA and CD were downloaded from the GEO database. Overlapping genes were identified using weighted gene co-expression network analysis and differential analysis crossover, and enrichment analysis was conducted for these genes. Protein-protein interaction networks were then constructed using these overlapping genes to identify hub genes. Expression validation and receiver operating characteristic curve validation were performed for these hub genes using different datasets. Additionally, the immune cell correlation, single-cell expression cluster, and the immune cell expression cluster of the core gene were analyzed. Furthermore, upstream shared microRNAs (miRNA) were predicted and a miRNA-gene network was constructed. Finally, drug candidates were analyzed and predicted. These core genes were found to be positively correlated with multiple immune cells that are infiltrated by the disease. Analysis of gene expression clusters revealed that these genes were mostly associated with inflammatory and immune responses. The miRNA-genes network analysis suggested that hsa-miR-31-5p may play an important role in the common mechanism of RA and CD. Finally, tamibarotene, retinoic acid, and benzo[a]pyrene were identified as potential treatment options for patients with both RA and CD. This bioinformatics study has identified ITGB2, LCP2, and PLEK as key diagnostic genes in patients with both RA and CD. The study has further confirmed that inflammation and immune response play a central role in the development of both RA and CD. Interestingly, the study has highlighted hsa-miR-31-5p as a potential key player in the common mechanism of both diseases, representing a new direction in research and a potential therapeutic target. These shared genes, potential mechanisms, and regulatory networks offer new opportunities for further research and may provide hope for future treatment of patients with both RA and CD.

2024-04-03·Cureus

How Do Retinoids Affect Alzheimer’s Disease and Can They Be Novel Drug Candidates?

Review

作者: Alsharief, Mazen

Alzheimer's disease is a chronic, neurological condition that faces many challenges in its management and therapy nowadays highlighting the importance and urgent need of researching new ways of approaching this disease. Retinoic acid and its derivatives, collectively known as the retinoids, are considered promising agents that have disease-modifying properties in affecting Alzheimer's disease. This thesis aims to address the research questions of what the role of retinoids is in Alzheimer's disease, and whether they can be used as a novel drug candidate for treating this condition. Retinoids' properties and agonistic actions on the nuclear receptors retinoic acid receptor (RAR) and retinoic X receptor (RXR) affect various pathways as well as their underlying genetic factors that compose important pathophysiological hallmarks causing the progression of Alzheimer's disease as amyloid β (Aβ) production and deposition, neurofibrillary tangle (NFT) formation and phosphorylation, and inflammatory and autoimmune responses. Retinoic acid inhibits the amplification of these pathways and modifies the disease progression in animal models, proposing a solid basis for human trials. Hence, investigating retinoids as pharmacological agents in human trials has been conducted, and several synthetic analogues have been developed to address issues concerning retinoic acid's instability and short half-life, as well as adverse drug reactions. The most prominent of these analogues is tamibarotene, a stable retinoic acid derivative with a higher half-life, higher specificity to target receptors, and fewer adverse reactions. A number of criteria that explain what a novel drug candidate should have when managing Alzheimer's disease have been formulated, and which also explain why most novel drug candidates other than retinoic acid have failed in achieving clinical results. Most of these candidates share one common trait which is a single-target approach in targeting disease pathways. This means that when administering these agents, their actions are to target a single disease-causing pathway at a time but do not affect other pathways. On the other hand, tamibarotene is a novel drug candidate that targets a range of pathways at once and provides a more comprehensive approach in its pharmacological actions.

93

项与他米巴罗汀相关的新闻（医药）

2024-11-30

·药事纵横

失败临床研究TOP9（2024年11月）

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。据不完全统计，今年11月共有9项临床研究宣告失败，小编将这些研究总结如下：罗氏：tiragolumab III期SKYSCRAPER-01研究 2024年11月26日，罗氏宣布其TIGIT抗体tiragolumab在3期 SKYSCRAPER-01研究中的最新进展，该研究评估了Tiragolumab联合 Tecentriq与单独使用Tecentriq对 PD-L1 高表达、局部晚期或转移性非小细胞肺癌 (NSCLC) 患者的疗效，该研究在最终分析时没有达到总生存率的主要终点。早在2022年，罗氏首次公布SKYSCRAPER-01试验未能达到PFS共同主要终点，尽管后来的数据显示治疗组的OS有改善趋势。这不是罗氏TIGIT抗体的第一次失败。2022年，tiragolumab 作为单药在广泛期小细胞肺癌的 3 期 SKYSCRAPER-02 研究中失败。2024年7月4日，罗氏宣布非鳞状非小细胞肺癌的II/III期临床研究SKYSCRAPER-06研究未达到主要终点。基于这些结果，罗氏打算停止这项研究。 2024年7月25日，罗氏发布上半年财报，同时更新了研发管线的最新调整，其中终止了4项三期临床，包括TIGIT抗体Tiragolumab治疗NSCLC的两项三期临床，一项为PD-L1+TIGIT+化疗一线治疗NSCLC，另一项为PD-L1+TIGIT术后辅助治疗NSCLC。 Cassava：Simufilam III期ReThink-ALZ研究 11月25日，Cassava Sciences宣布Simufilam治疗轻度至中度阿尔茨海默病（AD）的III期ReThink-ALZ研究未达到预先指定的双重主要终点以及次要终点和探索性生物标志物终点。受此消息影响，Cassava Sciences的股价当日下跌了84%。 Simufilam是一款靶向错构的细丝蛋白A（FLNA）的口服小分子药物。ReThink-ALZ研究评估了Simufilam（100mg，每日2次）对比安慰剂治疗轻度至中度AD患者的安全性和有效性。研究的主要终点是：第52周患者的认知功能（通过AD评定量表-认知功能子量表（ADAS-Cog12）评分评估）和第52周患者的日常生活能力（通过AD协作研究-日常生活能力量表（ADCS-ADL）评分评估）相比于基线的变化。结果显示，相比于安慰剂组，Simufilam组患者的ADAS-Cog12评分（+2.8分 vs +3.2分，Δ=-0.39分，P=0.43）和ADCS-ADL评分（-3.3分 vs -3.8分，Δ=0.51分，P=0.40）并未显著改善。天士力：安美木单抗II期临床试验 11月24日，天士力医药集团股份有限公司宣布：因临床试验结果不达预期，其间接控股子公司赛远生物安美木单抗项目临床试验暂停，目前该试验处于II期临床阶段，并对开发支出余额1.62亿元全额计提资产减值准备。公告披露，项目研发耗时近8年，截至公告日，安美木单抗项目研发投入共计1.89亿元，按照公司对赛远生物持股比例计算，计提资产减值准备将相应减少公司2024年度归母净利润9545.17万元。上述数据未经会计师事务所审计，最终数据以公司披露的 2024 年年度报告为准。重组全人源抗 EGFR 单克隆抗体注射液（安美木单抗）是一种主要用于治疗晚期实体瘤的1类治疗用生物制品，于2016年12月获得国家食品药品监督管理总局签发的 IND 临床试验批件。 2024 年 10 月出具的该项目《IIb 期临床研究报告（期中分析）》，结果提示安美木单抗与抗PD-1单抗和 FOLFIRI 化疗联用未增加毒性，免疫原性低，但与对照组 PFS（Progression-Free-Survival，无进展生存期）差异无统计学意义，未显示安美木单抗联合抗 PD-1 单抗具有协同增效作用，未能达到试验预设终点。截至期中分析时间点，IIb 期临床试验多数患者已出组，试验数据趋于成熟，预计期末分析结果和结论较期中分析不会有改变。 Eyenovia：MicroPine III期CHAPERONE研究 11月15日，眼科公司Eyenovia宣布验证MicroPine（阿托品局部微量制剂）延缓儿童近视进展效果的III期CHAPERONE研究未达到主要终点（3年内视力进展低于0.5屈光度）。Eyenovia计划终止这项研究，更彻底地审查数据，并评估下一步工作。受此消息影响，Eyenovia股价下跌了70%。 MicroPine是一种由Eyenovia基于其创新眼部用药平台Optejet开发的药物设备组合，包含0.1%或0.01%的阿托品，并通过微量定量喷雾形式给药。Eyenovia对这款产品寄予厚望，预计其峰值销售额有望超过10亿美元。 CHAPERONE研究是一项多中心、随机、双盲、安慰剂对照临床试验，评估了MicroPine对比安慰剂用于延缓儿童近视进展的疗效和安全性。独立数据审查委员会审查了252名可评估患者的安全性和有效性数据。在近视进展率方面，两个剂量组（0.01%和0.1% 阿托品眼用定量喷雾剂）和安慰剂之间的未达到显著差异。安全性分析显示，两个剂量和安慰剂似乎都具有良好的耐受性，不良事件轻微且发生率低。艾伯维：Emraclidine两项II期试验 11月12日，艾伯维宣布其用于治疗精神分裂症的M4激动剂Emraclidine在两项名为EMPOWER-1和EMPOWER-2的临床二期试验中，未达到其主要终点。受此消息的影响，艾伯维股价大跌超12%，市值蒸发约400亿美元。这意味着与安慰剂相比，Emraclidine在改善PANSS（Positive and Negative Syndrome Scale）总分方面没有统计学上的显著差异。 2023年12月，艾伯维以87亿美元收购了Cerevel Therapeutics及其后期资产Emraclidine。Emraclidine是一种毒蕈碱M4受体的正变构调节剂（PAM），被认为是一种潜在的下一代抗精神病药物。它通过选择性地调节M4受体来减少多巴胺信号，而不需要阻断D2受体，这可能减少现有抗精神病药物的副作用。 Syros：tamibarotene III期SELECT-MDS-1研究 11月12日，Syros Pharmaceuticals公司宣布，tamibarotene治疗新诊断RARA基因过表达高危骨髓增生异常综合征（HR-MDS）患者的III期临床SELECT-MDS-1未能达到主要终点目标，与对照组相比，Tamibarotene+Azacitidine联合疗法未能显著提高某些MDS患者的完全缓解率。 tamibarotene是一款口服视黄酸受体α (RARα)激动剂，最早日本由Nippon Shinyaku公司开发，2005年6月就已在日本被批准上市，用于治疗急性早幼粒细胞白血病。根据这次试验的数据，在接受Tamibarotene与Azacitidine治疗的患者中，完全缓解率（CR率）为23.8%，而对照组的CR率为18.8%，但统计学上并未达到显著意义（p= 0.2084）。Syros计划停止试验，深入审查临床数据，并评估未来的方向，以便在今后的治疗中找寻新的可能性。参考资料：各公司公告

临床3期财报临床失败临床2期临床结果

2024-11-15

·佰傲谷BioValley

Ⅲ期临床失败，触发贷款违约

近日，Syros Pharmaceuticals公司宣布，tamibarotene治疗新诊断RARA基因过表达高危骨髓增生异常综合征（HR-MDS）患者的III期临床SELECT-MDS-1未能达到主要终点目标，与对照组相比，Tamibarotene+Azacitidine联合疗法未能显著提高某些MDS患者的完全缓解率。 tamibarotene是全司押注希望的管线，先前公司停止在新诊断RARA过表达AML患者招募已经大大刺激了市场的神经，经历了70%的大跌。 MDS是tamibarotene目前推的最快的适应症，Syros指望着靠着这个临床成功来摆脱财务困境。 SELECT-MDS-1临床的失败再次加剧了市场的失望情绪，该临床结果公布后，公司股价急剧下跌，跌幅高达92%。希望管线破灭 tamibarotene是一款口服视黄酸受体α (RARα)激动剂，最早日本由Nippon Shinyaku公司开发，2005年6月就已在日本被批准上市，用于治疗急性早幼粒细胞白血病。视黄酸受体α是一种核受体，由RARA基因编码，大约50%的MDS患者和30%的AML患者表现出RARA基因的过表达。当RARA的表达量超过其严格控制的天然配体时，骨髓中的细胞可能无法分化成健康的髓细胞，从而导致血液恶性肿瘤。 Tamibarotene通过与过表达的RARA结合，帮助恢复髓细胞分化。2023年，Tamibarotene获得了FDA快速通道指定，用于治疗RARA过表达的高风险MDS患者。 SELECT-MDS-1主要评估Tamibarotene+Azacitidine对比Azacitidine+安慰剂在新诊断RARA过表达高危骨髓增生异常综合征（HR-MDS）患者中的安全性和有效性。结果显示，接受Tamibarotene+Azacitidine治疗的患者CR率为23.8%，而对照组（Azacitidine+安慰剂）的CR率为18.8%，虽然CR率前者更高，但是没有达到统计学显著差异。公司首席执行官Conley Chee在一份声明中表示了对这一结果的深感失望，公司将停止SELECT-MDS-1临床试验，在完成对后期临床数据的审查后评估下一步方案。此外，Tamibarotene在另一项适应症—AML中的临床疗效更加不理想。针对40名新诊断RARA过表达AML患者的预先设定分析结果显示(SELECT-AML-1)，Tamibarotene三联疗法组患者的CR/CRi率不及对照组（65% VS 70%)，公司认为在最终分析中，Tamibarotene三联疗法组显示出优势的可能性不大。在2024年8月，Syros宣布计划停止SELECT-AML-1的患者招募。该消息公布后，公司股价暴跌70%。从公司两次的股价反应看出，Tamibarotene连个临床试验挫折对公司打击之大，尤其是公司把已经十分紧张的资金都押注Tamibarotene上。 35%的裁员重组 Syros Pharmaceuticals由知名风险投资公司Flagship Pioneering孵化，成立于2011年，专注于基因调控疗法的开发。2022年9月收购了TYME公司后在纳斯达克交易市场上市。在公司去年重组前，共有8条管线在研，包括共2个临床后期管线和6个早期临床/临床前管线。然而去年，两个合作方的相继离开给公司打击很大。 2023年7月和8月，辉瑞（镰状细胞病和β-地中海贫血）和Incyte（骨髓增殖性肿瘤）相继终止与公司的合作协议，里程碑款项已经泡汤。同时公司Syros财务状况也堪忧，截至2023年9月30日，现金、现金等价物和有价证券为1.12亿美元。去年10月，Syros进行了重组来消减开支，临床前管线一律砍掉，只剩下Tamibarotene在内的三条管线在研，其中还暂停了SY-2101在急性早幼粒细胞白血病的临床开发。作为重组的一部分，还裁员了35%，公司的首席执行官、首席科学官也在此次人事变动之列。触发违约条款更加雪上加霜的是，SELECT-MDS-1临床失败还构成与Oxford Finance LLC贷款协议的违约。早在2020年，公司与Oxford Finance LLC签订了一项贷款和担保协议，该协议中协定了一些违约条款，其中就包括SELECT-MDS-1未达到临床主要终点。 Tamibarotene的失败也基本阻断了公司的再融资能力，2025年11月1日起，公司就要开始偿还本金。截至2024年9月30日，Syros现金及其现金等价物只有0.58亿美元。参考出处 https://www.biospace.com/drug-development/syros-crashes-over-90-on-late-stage-mds-fail-loan-default https://ir.syros.com/press-releases/detail/311/syros-reports-third-quarter-2024-financial-results-and https://www.nasdaq.com/press-release/syros-reports-third-quarter-2023-financial-results-and-provides-a-corporate-update 本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·

临床3期临床失败临床结果并购

2024-11-13

·EndPoints

Syros' shares plummet as blood cancer drug fails again

Syros Pharmaceuticals’ share price nosedived after its last drug candidate flunked a trial in hematological malignancies for the second time in recent months. In a 190-participant Phase 3 trial, the biotech’s tamibarotene plus azacitidine led to a 23.8% complete response rate in people with newly diagnosed higher-risk myelodysplastic syndromes and RARA gene overexpression versus 18.8% for azacitidine plus placebo. The result was not statistically significant with a p-value of 0.2084, according to a Tuesday release . Syros’ share price $SYRS was down 80% premarket Wednesday. The trial failure triggers a default event under the terms of Syros’ secured loan facility with Oxford Finance. The biotech plans to stop the trial, analyze the data and “evaluate the next steps,” CEO Conley Chee said in the release. The study flop comes just three months after an August disappointment for a tamibarotene triplet regimen in a Phase 2 study of newly diagnosed, unfit patients with acute myeloid leukemia and RARA gene overexpression. Tamibarotene is a retinoid acid receptor alpha agonist. “Tamibarotene’s demise brings to an end Syros’ last clinical program,” TD Cowen analysts said in a Wednesday note, adding the company is likely to end all development of the drug. The biotech previously stopped work on two other clinical candidates, SY-2101 and SY-5609, although it said on an earnings call last month it is looking for licensing opportunities for the latter. The company reported $58.3 million in cash and equivalents as of the end of September.

临床3期临床2期临床失败

100 项与他米巴罗汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01418	他米巴罗汀	L01X	DB04942

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性早幼粒细胞白血病	日本	Toko Pharmaceutical Industrial Co. Ltd.	2005-04-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
RARα阳性骨髓增生异常综合征	临床3期	美国	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	奥地利	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	比利时	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	加拿大	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	捷克	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	法国	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	德国	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	匈牙利	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	以色列	Syros Pharmaceuticals, Inc.	2021-02-08
RARα阳性骨髓增生异常综合征	临床3期	意大利	Syros Pharmaceuticals, Inc.	2021-02-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02807558 (CTgov)	临床2期	急性髓性白血病 \| 骨髓增生异常综合征	155	Tamibarotene (R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy)	壓淵膚遞顧顧鹹範鏇顧(鬱遞淵壓範襯鹹選網醖) = 構艱鏇壓鬱獵鏇餘壓鑰鬱衊淵壓鹹網憲繭顧製 (願夢衊壓遞獵夢衊鏇鏇, 鏇鬱壓範構壓醖壓糧艱 ~ 餘艱鹹鑰鏇製築憲願鬱) 更多	-	2024-12-13
				Tamibarotene (Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy)	壓淵膚遞顧顧鹹範鏇顧(鬱遞淵壓範襯鹹選網醖) = 遞艱齋窪鬱觸鏇蓋簾夢鬱衊淵壓鹹網憲繭顧製 (願夢衊壓遞獵夢衊鏇鏇, 壓壓蓋夢積廠製觸夢遞 ~ 顧觸簾夢繭製觸製顧鏇) 更多
NCT04797780 (SELECT-MDS-1, Company_Website) 人工标引	临床3期	高危骨髓增生异常综合征	190	Tamibarotene in combination with azacitidine	壓鏇艱憲選夢廠製構網(夢齋廠構窪夢觸襯獵艱) = 願選醖鑰齋鹹觸窪衊顧鬱衊糧憲網膚窪醖醖餘 (鏇簾襯網鏇簾鬱顧鏇壓, 16.7 ~ 32.2) 未达到	不佳	2024-11-12
				Placebo and azacitidine	壓鏇艱憲選夢廠製構網(夢齋廠構窪夢觸襯獵艱) = 窪廠鬱獵遞積觸壓餘網鬱衊糧憲網膚窪醖醖餘 (鏇簾襯網鏇簾鬱顧鏇壓, 10.1 ~ 30.5) 未达到
NCT04905407 (AML-347 SELECT-AML-1, SOHO2024)	临床2期	RARA阳性急性髓性白血病 RARA overexpression	80	Tamibarotene 6 mg PO BID + Venetoclax-Azacitidine	簾願糧獵繭鹽願選壓窪(鬱構鹽簾顧夢鏇衊廠醖) = 築鏇壓願廠衊繭糧壓襯艱獵膚鹽願窪構糧鑰蓋 (鏇鏇憲憲鏇醖膚選壓願 ) 更多	积极	2024-09-04
				Venetoclax-Azacitidine	簾願糧獵繭鹽願選壓窪(鬱構鹽簾顧夢鏇衊廠醖) = 觸鹽築衊襯廠積壓積壓艱獵膚鹽願窪構糧鑰蓋 (鏇鏇憲憲鏇醖膚選壓願 ) 更多
SELECT-AML-1 (NEWS) 人工标引	临床2期	RARA阳性急性髓性白血病 RARA	19	tamibarotene+venetoclax+azacitidine	鑰齋夢醖蓋淵蓋膚遞網(膚顧鑰範構鑰顧築網鹹) = 網觸餘選製醖選糧繭簾鹽膚艱獵顧廠觸鏇艱構 (網廠遞鹽窪窪繭衊壓鏇 ) 更多	积极	2023-12-07
				venetoclax+azacitidin	鑰齋夢醖蓋淵蓋膚遞網(膚顧鑰範構鑰顧築網鹹) = 繭鏇遞選鬱窪憲築積遞鹽膚艱獵顧廠觸鏇艱構 (網廠遞鹽窪窪繭衊壓鏇 ) 更多
NCT02807558 (Pubmed)	临床2期	急性髓性白血病	51	Tamibarotene plus azacitidine	夢鹽網夢築觸淵觸艱鑰(網構網遞蓋製衊鹹願網) = hematologic AEs were comparable to single agent azacitidine, demonstrating that there was no additional myelosuppression when tamibarotene was combined with azacitidine 鏇觸製餘廠憲壓襯窪膚 (艱鏇憲醖簾餘構廠繭鹽 ) 更多	-	2022-12-07
NCT04905407 (SELECT-AML-1, ASH 12022 \| ASH 22022) 人工标引	临床2期	RARA阳性急性髓性白血病一线 RARA	6	Venetoclax+Azacitidine+Tamibarotene	鹹鬱選鏇衊醖獵遞願選(選願廠鬱鬱鬱獵糧觸餘) = occurring in more than one patient was febrile neutropenia 窪積積遞繭鏇壓製築積 (蓋衊觸獵廠構糧鑰顧鏇 ) 更多	积极	2022-11-15
				Venetoclax+Azacitidine
NCT04905407 (SELECT-AML-1, SOHO2022)	临床2期	RARA阳性急性髓性白血病 RARA-positive	-	Tamibarotene/venetoclax/azacitidine	夢鏇蓋繭鏇鹽膚積範鏇(糧鬱夢鏇廠淵淵築顧獵) = 選糧顧窪糧築淵襯鹽窪鬱衊蓋鹽顧憲膚憲壓餘 (鹽築積獵獵積觸醖築膚 )	-	2022-10-01
NCT02807558 (ASH 12020 \| ASH 22020) 人工标引	临床2期	复发性急性髓细胞白血病 RARA Positive	28	Azacitidine+SY-1425	壓構積範願鬱鹹觸膚鹹(淵醖鬱壓遞簾膚膚醖鹽) = 憲鹽衊繭糧衊繭遞窪艱襯鏇網淵構衊膚顧觸蓋 (壓鹹顧壓窪鏇願蓋衊選 ) 更多	积极	2020-11-05
NCT02807558 (ASH 12020 \| ASH 22020) 人工标引	临床2期	RARA阳性急性髓性白血病一线 RARA	51	Azacitidine+SY-1425 (RARA+)	壓鏇膚繭繭襯廠構窪範(糧構廠範顧廠窪齋衊窪) = febrile neutropenia (27%), pyrexia (12%), pneumonia (12%), and sepsis (10%). 淵廠襯蓋構衊膚築餘衊 (鹽簾淵鹽構選繭觸廠餘 ) 更多	积极	2020-11-05
				Azacitidine+SY-1425 (RARA-)
NCT02807558 (ASH 12018 \| ASH 22018) 人工标引	临床2期	急性髓性白血病 \| 骨髓增生异常综合征	10	azacitidine+SY-1425	築簾製簾獵膚淵鑰鹹膚(淵顧窪願鹹壓膚醖鬱鬱) = febrile neutropenia (44%), and hypertriglyceridemia, pruritus, abdominal pain and peripheral edema (33% each). 鹽觸膚網構鏇遞範壓選 (壓築築積壓鹽繭遞鏇餘 )	积极	2018-11-29
				daratumumab+SY-1425